Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.

Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundarò C, Gasbarrini A.

Eur Rev Med Pharmacol Sci. 2013 May;17(10):1314-20.

2.

[Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].

Liu ZJ, Wei H, Duan LP, Zhu SW, Zhang L, Wang K.

Zhonghua Yi Xue Za Zhi. 2016 Jun 28;96(24):1896-902. doi: 10.3760/cma.j.issn.0376-2491.2016.24.005. Chinese.

PMID:
27373356
3.

Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.

Collins BS, Lin HC.

J Pediatr Gastroenterol Nutr. 2011 Apr;52(4):382-6. doi: 10.1097/MPG.0b013e3181effa3b.

PMID:
21240023
4.

Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study.

Scarpellini E, Giorgio V, Gabrielli M, Lauritano EC, Pantanella A, Fundarò C, Gasbarrini A.

J Pediatr. 2009 Sep;155(3):416-20. doi: 10.1016/j.jpeds.2009.03.033. Epub 2009 Jun 16.

PMID:
19535093
5.

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.

Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A.

World J Gastroenterol. 2009 Jun 7;15(21):2628-31.

6.

Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.

Moraru IG, Portincasa P, Moraru AG, Diculescu M, Dumitraşcu DL.

Rom J Intern Med. 2013 Jul-Dec;51(3-4):143-7.

PMID:
24620626
7.

Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome.

Rana SV, Sharma S, Kaur J, Sinha SK, Singh K.

Digestion. 2012;85(3):243-7. doi: 10.1159/000336174. Epub 2012 Mar 30.

PMID:
22472730
8.

Microscopic colitis and small intestinal bacterial overgrowth--diagnosis behind the irritable bowel syndrome?

Stoicescu A, Andrei M, Becheanu G, Stoicescu M, Nicolaie T, Diculescu M.

Rev Med Chir Soc Med Nat Iasi. 2012 Jul-Sep;116(3):766-72.

PMID:
23272525
9.

A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.

Zhao J, Zheng X, Chu H, Zhao J, Cong Y, Fried M, Fox M, Dai N.

Neurogastroenterol Motil. 2014 Jun;26(6):794-802. doi: 10.1111/nmo.12331. Epub 2014 Mar 18.

PMID:
24641100
10.

Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania.

Moraru IG, Moraru AG, Andrei M, Iordache T, Drug V, Diculescu M, Portincasa P, Dumitrascu DL.

Rom J Intern Med. 2014;52(3):143-50.

PMID:
25509557
11.

Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.

Weinstock LB, Geng B, Brandes SB.

Can J Urol. 2011 Aug;18(4):5826-30.

PMID:
21854715
12.

Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome.

Boltin D, Perets TT, Shporn E, Aizic S, Levy S, Niv Y, Dickman R.

Ann Clin Microbiol Antimicrob. 2014 Oct 17;13:49. doi: 10.1186/s12941-014-0049-x.

14.

Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.

Bae S, Lee KJ, Kim YS, Kim KN.

J Korean Med Sci. 2015 Jun;30(6):757-62. doi: 10.3346/jkms.2015.30.6.757. Epub 2015 May 13.

15.

Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome.

Triantafyllou K, Sioulas AD, Giamarellos-Bourboulis EJ.

Mini Rev Med Chem. 2015;16(3):186-92. Review.

PMID:
26202193
16.

Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?

Aziz I, Törnblom H, Simrén M.

Curr Opin Gastroenterol. 2017 May;33(3):196-202. doi: 10.1097/MOG.0000000000000348. Review.

PMID:
28257307
17.

Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin.

Cuoco L, Salvagnini M.

Minerva Gastroenterol Dietol. 2006 Mar;52(1):89-95.

PMID:
16554709
18.

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.

Meyrat P, Safroneeva E, Schoepfer AM.

Aliment Pharmacol Ther. 2012 Dec;36(11-12):1084-93. doi: 10.1111/apt.12087. Epub 2012 Oct 16.

19.

Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.

Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW.

Am J Med Sci. 2007 May;333(5):266-70.

PMID:
17505166
20.

Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.

Lauritano EC, Gabrielli M, Scarpellini E, Ojetti V, Roccarina D, Villita A, Fiore E, Flore R, Santoliquido A, Tondi P, Gasbarrini G, Ghirlanda G, Gasbarrini A.

Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):111-6.

PMID:
19499846

Supplemental Content

Support Center